Watch the video and download the slides

LYMPHOMA & MYELOMA CONNECT Expert Dr. Tycel Phillips discusses highlights in lymphoma, focusing on recently approved agents in diffuse large B-cell lymphoma and follicular lymphoma, and where they fit in the current treatment landscape.


Watch the video and download the slides


Subtitles in English are available by clicking on ‘CC’ within the video controls

Video Transcript


Highlights in non-Hodgkin Lymphoma – Diffuse-Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)




Hello, my name is Dr Tycel Phillips. I’m an Associate Professor at the University of Michigan, Ann Arbor, United States. I’d like to thank you for taking the time to listen to this presentation about the new and improved agents in patients with large cell lymphoma and follicular lymphoma.

Within the last 6-12 months there have been several new agents approved for the treatment of patients with diffuse large B-cell lymphoma and follicular lymphoma. What we will do is discuss these agents and where they fit into our clinical practice.


Loncastuximab tesirine in DLBCL– LOTIS-2 study


The first agent that I’ll discuss is loncastuximab tesirine, which is a CD19 drug-antibody conjugate. The drug that is conjugated to this antibody is a PBD dimer toxin, which causes irreversible DNA and intra-strand crosslinks causing a block in DNA separation and DNA replication. This agent was approved for third-line diffuse-large B-cell lymphoma, based on the results of LOTUS-1 and LOTUS-2. In the LOTUS-2 study, there was an overall response rate of 48.3% with a complete remission rate of 24.1%. The median duration of response was 10.3 months.

The key takeaways from this study would be that this agent is given every 3 weeks, so the treatment duration is fairly reasonable for patients. The drug is dosed at 150 µg/kg for the first two cycles and thereafter drops to 75 µg/kg, to reduce some of the toxicities noted with this agent. Overall, the toxicity profile was manageable and there are some medications that can be given prophylactically to help prevent some of the AEs. But from data presented it did appear this agent was tolerable for elderly and young patients with diffuse-large B-cell lymphoma.


Lenalidomide + tafasitamab-cxix in DLBCL – L-MIND study


The next agent that we will talk about in this patient population is lenalidomide and tafasitamab. Lenalidomide is an immunomodulatory agent that we are all aware of, whereas tafasitamab is a CD19 drug-antibody conjugate. Tafasitamab was given in 12 mg/kg IV, days 1, 8, 15 and 22. Whereas lenalidomide was given as 25 mg on days 1-21, with 7 days off. After the first three cycles, the administration of tafasitamab changes to days 1 and 15 and after the cycle 12 lenalidomide is dropped, and tafasitamab is given as a single agent, on days 1 and 15.

The overall response rate from this study was fairly reasonable, with 36.5-months of follow-up showing 57.5% overall response rate, a complete remission rate of 40% and a partial response rate of 17.5%. The median duration of response was 43.9 months, the median progression-free survival was 11.6 months, and the median overall survival was 33.5 months.

This study was a little bit different from loncastuximab in that it was given for patients with 1-3 prior lines of therapy, and it did at some point exclude patients with primary refractory disease. The overall response rate is impressive, but this drug appears to be more so of function for patients who have relapsed disease versus those who have primary refractory disease, and more follow-up in regular clinical practice will be needed to see how applicable this treatment regimen is to patients with more refractory disease that we’d typically see in our clinical practice.


Conclusion on DLBCL


All in all, both these agents for large cell lymphoma have had added to our clinical algorithm of drugs that we can use for these patients and will hopefully improve some of the clinical outcomes we have in patients who are either intolerant to or fail autologous stem-cell transplantation or CAR-T therapy.


Axicabtagene ciloleucel in FL– ZUMA-5 study


Now, we will switch gears to follicular lymphoma. At this time, we will talk about axi-cel, which is a CAR-T therapy.

Axi-cel was studied in the ZUMA-5 study, where it was studied in patients with relapsed/refractory indolent non-Hodgkin lymphoma. This study demonstrated an overall response rate of 92% overall, with 94% in follicular lymphoma and a complete remission rate of 80% for follicular lymphoma. The median follow-up was a bit short, but 64% of the patients with follicular lymphoma remain in response and responses were on-going in 78% of those who obtained a complete remission.

The safety profile of the treatment was very manageable in follicular lymphoma compared with what we would see in diffuse-large B-cell lymphoma. And of note, there were no grade 5 neurological events, and there was only one grade 5 cytokine release event noted in the study.


Conclusion on FL


Given how follicular lymphoma is a very convoluted market there are multiple agents that can be given in these patients, I think longer follow-up of this treatment is needed, given the cost associated with CAR-T therapy and some of the associated side effects.

The benefits of CAR-T: obviously it’s a one-time treatment but how this compares to some of the other agents that are approved in this setting, will be valuable, especially with the evaluations of the median follow-up, the duration of response in these patients, and also where bispecific antibodies fit into this picture, given that follicular lymphoma as of right now still remains incurable.


Key takeaways


I hope you appreciated and could glean some valuable information from this presentation.

I think, in the last year with some of these new approvals added to a lot of agents we can use in this patient population. Especially in diffuse large B-cell lymphoma, we have two new agents approved in the last 6-12 months that appear to be very effective in the patient population. How we sequence these agents and how we apply these will be something that we need to tease out with more clinical practice, outside of a clinical trial setting and sort out what patients are best utilized with these sort of treatments.

In follicular lymphoma we now have the approval of CAR-T, which is a monumental step, as far as trying to improve some of the outcomes in our patients. Where do we sequence CAR-T in this patient population? How long is the response and how will they compare to some of the treatments which may have a little bit better of a safety profile over far more frequent treatments?

With that I conclude my presentation and I thank you for joining in.

Dr Tycel Phillips, is a lymphoma specialist with a research and clinical focus on non-hodgkin lymphoma.  Dr Phillips completed his hematology-oncology fellowship at University Hospitals/Case Western University.  While at Case Western, Dr Phillips began to focus on the development of clinical trials utilizing novel agents in lymphoma.  He has continued his focus on clinical research upon his appointment at the University of Michigan and in addition has been the site primary investigator on numerous clinical trials in multiple subtypes of lymphoma. Dr Phillips’s research interests include evaluation of resistance mechanisms in mantle cell lymphoma (MCL), non-cytotoxic chemotherapeutic treatment in frontline MCL, and other novel combinations in relapsed/refractory lymphoma. Dr Phillips is involved in professional societies including the American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH).

Programme summary
Play the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
I agree that this educational programme:

Was valuable to me

Brought to you by

LYMPHOMA & MYELOMA CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer and from Karyopharm Therapeutics.

Meet the experts

Other programmes of interest

conference-update Conference update



of 6

Oncology Obstetrics and Gynecology Hemato-oncology 
Listen to Expert Insights on Late-Breaking Data from ASCO 2023

Episode 1: Non-Small-Cell Lung Cancer Update: ADAURA trial

Dr Mansoor Raza Mirza, Dr Paolo Tarantino, Prof. Alexey V Danilov, Prof. Mark Socinski, Prof. Evan Yu, Prof. Thomas Powles, Assoc. Prof. Gerald Prager
  • clock 2 MIN
  • calendar Jun 2023

Oncology Hemostasis and bleeding disorders Hemato-oncology 
Update From ASH 2022

Highlights from the ASH Annual Meeting

Dr Matthew J. Matasar
  • clock 4 MIN
  • calendar Dec 2022

Educational programme supported by an independent medical education grant from COR2ED.
Update from ASCO 2022 – Myeloma

Dr Hans Lee summarises the highlights from the phase 3 DETERMINATION trial: Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM)

Asst. Prof. Hans Lee
  • clock 2 MIN
  • calendar May 2022

podcast Podcast



of 3

Choosing the Best Treatment Regimen in Patients with High-Risk Cytogenetics

Episode 3: Choosing the Best Treatment Regimen in Patients with High-Risk Cytogenetics

Assoc. Prof. María Victoria Mateos, Dr Alexander M Lesokhin
  • download Downloadable
  • clock 20 MIN
  • calendar Mar 2022

Educational programme supported by an independent medical education grant from Karyopharm
Lymphoma Update from ASH 2021

Dr. Matthew J. Matasar summarises the highlights in lymphoma from ASH 2021, including POLARIX, CAR-T in LBCL and mosunetuzumab in FL

Dr Matthew J. Matasar
  • download Downloadable
  • clock 5 MIN
  • calendar Dec 2021

Educational programme supported by an independent medical education grant from Bayer
DLBCL Review Paper Published in The Oncologist

Authored by LYMPHOMA & MYELOMA CONNECT members, the paper ‘Translating the Biology of Diffuse Large B-cell Lymphoma into Treatment’ provides an overview of recent advances in DLBCL biology and how they can be translated into clinical care.

Dr Matthew J. Matasar, Dr Massimo Magagnoli, Prof. Alexey V Danilov
  • download Downloadable
  • clock 5 MIN
  • calendar Nov 2021

Educational programme supported by an independent medical education grant from Bayer